Skip to content
Open access

Generation and characterization of three human induced pluripotent stem cell lines from patients with Duchenne muscular dystrophy.

Aug 2026 · Stem Cell Research · Vol 95, pp. 104074 · 0 citations · 2 references
Medicine

TL;DR

Three induced pluripotent stem cell lines reprogrammed from peripheral blood mononuclear cells (PBMCs) of patients with DMD constitute a relevant human cellular model for studying disease-associated phenotypes and evaluating potential therapeutic strategies.

Abstract

Duchenne muscular dystrophy (DMD) is a rare X-linked recessive disorder caused by mutations in the DMD gene, resulting in the absence of functional dystrophin. The loss of dystrophin disrupts the dystrophin-associated protein complex (DAPC), leading to progressive degeneration of skeletal and cardiac muscles. Clinically, DMD is characterized by proximal muscle weakness, respiratory insufficiency, and dilated cardiomyopathy. Here, we report the generation of three induced pluripotent stem cell (iPSC) lines reprogrammed from peripheral blood mononuclear cells (PBMCs) of patients with DMD. These patient-derived iPSC lines constitute a relevant human cellular model for studying disease-associated phenotypes and evaluating potential therapeutic strategies.

Read PDF

Similar papers

Open access Aug 2026

Generation of two induced pluripotent stem cell lines from Marfan syndrome patients carrying FBN1 mutations

Induced pluripotent stem cell lines derived from two Marfan syndrome patients with mutations in the FBN1 gene exhibited typical iPSC morphology, normal karyotype, undifferentiated states, and trilineage differentiation capacity.

Byron W H Mui, M. Chorsi, Christopher D. Yan et al. · 1 citation
Open access Aug 2026

Generation and characterization of human induced pluripotent stem cell line AUSCIi001-A from spinal muscular atrophy patient.

The established induced pluripotent stem cell line AUSCIi001-A from erythroid progenitor cells enriched from peripheral blood mononuclear cells of a 2-year-old male individual with SMA is established using the integration-free Sendai reprogramming method.

Ekin Doğan, Z. Aksoy, B. Ergin et al. · 0 citations
Open access Aug 2026

Generation of two induced pluripotent stem cell lines from Fabry disease patients carrying GLA mutations

Fabry disease is a rare genetic disease caused by loss-of-function in the GLA gene. This gene encodes the lysosomal enzyme α-galactosidase A (α-Gal A). A deficiency of α-Gal A results in the globotriaosylceramide buildup throughout the major organs, which is associated with increased mortality from cardiac disease in p...

Debarun Patra, D. Cabrera, Xiaochun Yang et al. · 0 citations
Open access Aug 2026

Derivation of a new induced pluripotent stem cell line ORIONi004-A for modelling Duchenne muscular dystrophy.

Peripheral blood was used as source for primary cells and subsequently reprogrammed into induced pluripotent stem cells with synthetic Sendai vector, which showed the expression of pluripotency factors and the ability to differentiate into all three germ layers.

Dominika Hajduchova, Stanislava Suroviaková, S. Mersakova et al. · 0 citations
Open access Aug 2026

Establishment of induced pluripotent stem cell line TRNDi045-A-38 carrying homozygous DOK7-related Congenital Myasthenia patient-mutation knock-in variant from parental KOLF2.1J.

A human induced pluripotent stem cell line TRNDi045-A-38 from the KOLF2.1J reference line is generated, engineered to carry homozygous DOK7 c.1124_1127dupTGCC mutation knock-in using CRISPR/Cas9, and could be used for in vitro disease modeling to study disease pathophysiology and for therapeutic development.

B. M. Jones, Miao Xu, J. Zou et al. · 0 citations
Open access Aug 2026

Generation and characterization of a patient-specific human induced pluripotent stem cell line from a Skogholt syndrome patient (ASCFi003-A)

This patient-specific iPSC line provides a valuable resource for generating choroid plexus organoids and neurons to investigate disease mechanisms and develop therapeutic strategies to investigate disease mechanisms and develop therapeutic strategies.

Weronika Przybala, Swapnil Gupta, H. Fjerdingstad et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.